Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Characterization of the binding of the novel compound GT-002 to GABAA receptors in the mammalian brain: Development and validation of a radioligand binding assay. A comparative study to Flumazenil
Linköping University, Department of Physics, Chemistry and Biology.
2017 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Gamma-Amino butyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central nervous system (CNS) and inhibits the neurotransmission by targeting the ionotropic transmembrane GABAA receptor. Modulators of the GABAA receptor targets the allosteric binding sites and modifies the GABA effect and these sites acts as superior drug targets within psychopharmacology.

 

Gabather AB has developed the novel compound GT-002 that is known to target the receptor and cause a behavioral effect in rodents. This project characterized the binding of the lead compound GT-002 to GABAA receptor in mammalian brain tissue by development and validation of a radioligand binding assay. In the assay a comparative evaluation was performed using the benzodiazepine (BZ) antagonist Flumazenil (FLU).

 

All experiments were performed using GABAA receptors originating from porcine and mouse brain tissue membrane, where no significant difference between the mammals was displayed. GT-002 binds with higher affinity and associates faster than FLU to the receptor and implies a two-binding site model. GT-002 displaced FLU and no tested competitive analytes targeting various modulatory sites of the receptor displaced GT-002, implying independent binding of GT-002 and allosterically impacts the BZ binding site.

Place, publisher, year, edition, pages
2017. , p. 45
Keyword [en]
GABAA receptor, Radioligand binding assay, GT-002, Triazoloquinazolinedione, Flumazenil, Neuropharmacology
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-143817ISRN: LITH-IFM-A-EX--17/3432--SEOAI: oai:DiVA.org:liu-143817DiVA, id: diva2:1168138
External cooperation
Gabather AB
Subject / course
Chemical Biology
Presentation
2017-12-15, Bikupan, Linköping, 13:15 (English)
Supervisors
Examiners
Available from: 2017-12-20 Created: 2017-12-20 Last updated: 2017-12-20Bibliographically approved

Open Access in DiVA

fulltext(2624 kB)69 downloads
File information
File name FULLTEXT01.pdfFile size 2624 kBChecksum SHA-512
37828f732d373a7e6849628d30d2b9cd7f818f883020fa5ed62a18fdf82b67cb9287e565329c5ea89978cc1f3fe2731a5e81b14c3b4163c98adfc237d68a5f53
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Emelie, Zemowska
By organisation
Department of Physics, Chemistry and Biology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 69 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 354 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf